Jobs
Alnylam
Alnylam
Focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
RNA Interference
Gene Therapy
Drug Development
Biomedical Research
Open Positions
0 positions
No open positions at this time
Products & Services
ON
ONPATTRO (patisiran)
RNAi Therapeutic
GI
GIVLAARI (givosiran)
RNAi Therapeutic
OX
OXLUMO (lumasiran)
RNAi Therapeutic
AM
AMVUTTRA (vutrisiran)
RNAi Therapeutic
LE
LEQVIO (inclisiran)
RNAi Therapeutic
RN
RNAi Platform Technology
Technology Platform
CE
Cemdisiran
Pipeline Drug
AL
ALN-APP
Pipeline Drug
FI
Fitusiran
Pipeline Drug
DR
Drug Development Services
Services
Similar Companies
Insulet
Public
Multinational healthcare company.
Bedford, Massachusetts, United States
501-1,000
Vertex
Biopharmaceutical company.
Boston, Massachusetts
Freenome
Series C
AI genomics company for cancer detection
South San Francisco, CA
201-500
Valuation $2.3B
29 open jobs
Editas Medicine
Public
Genome editing company
Cambridge, Massachusetts, United States
201-500
Edwards Lifesciences
Public
Medical devices for heart disease
Irvine, California, United States
10,001+
Mammoth Biosciences
Biotechnology company.
San Francisco, California, United States
51-200
1 open jobs
News & Buzz
All
X
News
HN
YouTube
Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth - Insider Monkey
Source: Insider Monkey
google-news
·
1mo ago
Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Source: MarketBeat
google-news
·
1mo ago
H.C. Wainwright raises Alnylam Pharmaceuticals stock price target on TTR franchise potential - Investing.com
Source: Investing.com
google-news
·
1mo ago
Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy - Finviz
Source: Finviz
google-news
·
1mo ago
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Source: BioSpace
google-news
·
1mo ago
More (11 remaining)
Total Views
0
Apply Clicks
0
Mock Applicants
0
Scraps
0
Reviews
4.1
10 reviews
Work Life Balance
4.2
Compensation
4.0
Culture
4.1
Career
3.8
Management
3.5
78%
Recommend to a Friend
Pros
Great people and team environment
Work-life balance and flexibility
Excellent science and innovation focus
Cons
Leadership out of touch
Growing pains
Heavy workload requirements
Salary Ranges
57 data points
Director
Intern
Mid/L4
Senior/L5
Director
1 reports
$260,000
total / year
Base
$200,000
Stock
-
$260,000
$260,000
Interview Experience
3 interviews
Difficulty
3.0
/ 5
Duration
2-5w
Experience
Positive 0%
Neutral 33%
Negative 67%
Interview Process
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Panel Interview
5
Final Round Interview
6
Offer
Contact & Location